Vaxart struck a partnership with Dynavax in November 2025 (Dynavax was acquired by Sanofi in February 2026), receiving a $25 million upfront payment plus a $5 million equity investment and becoming ...

For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and manufacturing costs associated with the development of soquelitinib as ...

We're handing out report cards on big moves, including the Jonathan Allen signing and Osa Odighizuwa trade.